US EditionAkadeum Life Sciences Lands Major Investment to Fuel Growth in Cell and Gene Therapy
- Akadeum Life Sciences closed a financing round exceeding $20 million on June 3, 2025, in Ann Arbor, Michigan, led by Michigan Capital Network.
- The investment comes shortly after Akadeum introduced a suite of products meeting GMP standards, aimed at supporting the development of advanced cell therapies in clinical research.
- Akadeum pioneered buoyancy-based cell separation technology and has introduced innovations like scalable negative selection and multiplex separation to support therapeutic manufacturing.
- Dan Kidle highlighted that Akadeum’s technology reliably produces greater quantities of healthy cells and improves efficiency compared to traditional approaches, while CEO Brandon McNaughton expressed his appreciation for investors who believe in their mission to transform access to advanced cell therapies.
- The funding will scale commercial operations and clinical trial support as Akadeum gains strong momentum and growing interest from biopharma partners like Catalent and Lonza.
26 Articles
26 Articles
Journal Gazette & Times-Courier
Akadeum Life Sciences Lands Major Investment to Fuel Growth in Cell and Gene Therapy
ANN ARBOR, Mich., June 3, 2025 /PRNewswire/ -- Akadeum Life Sciences, a pioneer in buoyancy-based cell separation technology, today announced the successful close of a $20 million+ financing round. The round was led by Michigan Capital Network, with strong participation…
Akadeum Life Sciences Raises $20M+ in Funding
Akadeum Life Sciences, an Ann Arbor, MI-based company which specializes in buoyancy-based cell separation technology, raised $20M+ in funding. The round was led by Michigan Capital Network, with participation from Arboretum Ventures, NYBC Ventures, and other investors. The company intends to use the funds to scale commercial operations and especially support customers entering clinical trials. […] The post Akadeum Life Sciences Raises $20M+ in F…
Coverage Details
Bias Distribution
- 92% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
